Roche's Perjeta gets early breast cancer thumbs-up in Europe; NICE solicits new comments on controversial diabetes guidelines;

> Roche's ($RHHBY) Perjeta won a European recommendation for use before surgery in women with HER2-positive breast cancer. Release

> Cost-effectiveness watchdogs in England bowed to pressure to reopen comments about new draft guidelines for treating diabetes, which have drawn considerable fire since the agency first unveiled them. Report

> European officials won't back down from urging Ireland to cut its spending on branded drugs, despite objections from the pharma industry. Report

> Regeneron's ($REGN) vision drug Eylea won a new indication in Japan to treat macular edema caused by blocked blood vessels in the retina. Report

> Johnson & Johnson ($JNJ) launched its new 1-Day Acuvue Moist brand multifocal contact lens, with new versions tailored to individual patients' pupil size. Report

And Finally... Doctors are more impressed with the potential for electronic health records to improve patient care than they are with Big Data number-crunching. Report

Suggested Articles

Sanofi's Sarclisa is coming full-force at Johnson & Johnson blockbuster Darzalex in the multiple myeloma field—now backed by new data.

Merck CEO Ken Frazier has spoken passionately about racism before. Monday, amid protests over George Floyd's death, he made that passion personal.

BMS is pricing Zeposia at the wholesale acquisition cost of $86,000, lower than the tag on Novartis' in-class rival Mayzent.